Rongchang Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rongchang Li has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Caiguang Liu
Department of Gastroenterology The First Affiliated Hospital of Sun Yat‐Sen University Guangzhou China
2 shared publicationsMinhu Chen
Department of Gastroenterology The First Affiliated Hospital of Sun Yat‐Sen University Guangzhou China
2 shared publicationsZihao Lin
Department of Gastroenterology The First Affiliated Hospital of Sun Yat‐Sen University Guangzhou China
2 shared publicationsCanhui Sun
Department of Radiology The First Affiliated Hospital of Sun Yat‐sen University Guangzhou China
1 shared publication- Chuhuai Wang
Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication Guang Yang
Shanghai Key Laboratory of Magnetic Resonance East China Normal University Shanghai China
1 shared publication
Latest Publications
- Open Access
- 3 April 2026
- Published by Wiley in Interdisciplinary Medicine
- Vol. 4 (4)
Multimodal MRI and multiomics reveal high‐risk neurophenotype in brain‐gut circuits as therapeutic target for Crohn's disease
The brain‐gut axis shapes Crohn's disease (CD) pathogenesis, yet CD‐associated neurophenotypes lack defined clinical and mechanistic significance. This work aimed to define these neurophenotypes, assess their prognostic impact, elucidate neurophenotype‐driven progression mechanisms using multi‐omics, and validate their therapeutic potential in vivo. 109 CD patients were prospectively recruited from two centers and underwent baseline multimodal neuro‐MRI, MR enterography, ileocolonoscopy, and fecal/blood sample collection. The neurophenotypes were characterized using a multimodal neuro‐MRI model developed from 13 of 13,870 features. 83 patients were followed up for disease progression, with repeated brain‐gut assessments. Multi‐omics (fecal microbiome/metabolomics, serum metabolomics/neurotransmitters) were used to decode the mechanisms underlying neurophenotype‐driven progression. Dextran sulfate sodium (DSS)‐induced colitis mice with different neurophenotypes were treated with repeated transcranial magnetic stimulation (rTMS) to explore its therapeutic potential. Multimodal neuro‐MRI accurately mapped CD‐specific neural signatures, stratifying patients into high‐risk (neurophenotype score ≥ 0.45) and low‐risk neurophenotypes with robust cross‐center validity (training cohort AUC = 0.842, test cohort AUC = 0.824). High‐risk neurophenotype was identified as an independent predictor of accelerated disease progression (Hazard ratio = 15.46, p = 0.030), independent of intestinal inflammation. Integrated multi‐omics revealed that the high‐risk neurophenotype contributed to CD progression through microbial‐metabolic‐neurotransmitter networks where tryptophan emerged as the central regulatory hub. Serum tryptophan levels were negatively correlated with neurophenotype severity and intestinal disease progression. rTMS targeting high‐risk neurophenotype in DSS‐induced colitis mice elevated tryptophan levels and ameliorated intestinal disease activity. This study redefines the high‐risk neurophenotype as a sustained pathogenic driver rather than a mere phenomenon, proposing brain‐gut axis modulation as a promising therapeutic strategy distinct from conventional anti‐inflammatory approaches.
- 3 April 2026
- Published by Wiley in Interdisciplinary Medicine
- Vol. 4 (4)
Open AccessMultimodal MRI and multiomics reveal high‐risk neurophenotype in brain‐gut circuits as therapeutic target for Crohn's disease
The brain‐gut axis shapes Crohn's disease (CD) pathogenesis, yet CD‐associated neurophenotypes lack defined clinical and mechanistic significance. This work aimed to define these neurophenotypes, assess their prognostic impact, elucidate neurophenotype‐driven progression mechanisms using multi‐omics, and validate their therapeutic potential in vivo. 109 CD patients were prospectively recruited from two centers and underwent baseline multimodal neuro‐MRI, MR enterography, ileocolonoscopy, and fecal/blood sample collection. The neurophenotypes were characterized using a multimodal neuro‐MRI model developed from 13 of 13,870 features. 83 patients were followed up for disease progression, with repeated brain‐gut assessments. Multi‐omics (fecal microbiome/metabolomics, serum metabolomics/neurotransmitters) were used to decode the mechanisms underlying neurophenotype‐driven progression. Dextran sulfate sodium (DSS)‐induced colitis mice with different neurophenotypes were treated with repeated transcranial magnetic stimulation (rTMS) to explore its therapeutic potential. Multimodal neuro‐MRI accurately mapped CD‐specific neural signatures, stratifying patients into high‐risk (neurophenotype score ≥ 0.45) and low‐risk neurophenotypes with robust cross‐center validity (training cohort AUC = 0.842, test cohort AUC = 0.824). High‐risk neurophenotype was identified as an independent predictor of accelerated disease progression (Hazard ratio = 15.46, p = 0.030), independent of intestinal inflammation. Integrated multi‐omics revealed that the high‐risk neurophenotype contributed to CD progression through microbial‐metabolic‐neurotransmitter networks where tryptophan emerged as the central regulatory hub. Serum tryptophan levels were negatively correlated with neurophenotype severity and intestinal disease progression. rTMS targeting high‐risk neurophenotype in DSS‐induced colitis mice elevated tryptophan levels and ameliorated intestinal disease activity. This study redefines the high‐risk neurophenotype as a sustained pathogenic driver rather than a mere phenomenon, proposing brain‐gut axis modulation as a promising therapeutic strategy distinct from conventional anti‐inflammatory approaches.
- Open Access
- 1 May 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (7) , 1092-1106
Gut Microbiota as a Mediator Between Intestinal Fibrosis and Creeping Fat in Crohn's Disease
Intestinal stricture remains one of the most challenging complications in Crohn's disease, and its underlying mechanisms are poorly understood. Accumulating evidence suggests that gut microbiota is significantly altered in stenotic intestines and may play a key role in the development of fibrogenesis in Crohn's disease. Additionally, the presence of hypertrophic mesenteric adipose tissue, also known as creeping fat, is closely correlated with intestinal stricture and fibrosis. Recent findings have revealed that bacterial translocation to creeping fat might exacerbate colitis and promote intestinal fibrosis. However, there is still a gap in determining whether gut microbiota links the formation of creeping fat to intestinal fibrosis. Hence, this review aims to summarize the known microbial influences on intestinal fibrosis, describes the microbial characteristics of creeping fat in Crohn's disease, and discusses the crosstalk between creeping fat‐associated dysbiosis and the development of intestinal fibrosis.
- 1 May 2025
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (7) , 1092-1106
Open AccessGut Microbiota as a Mediator Between Intestinal Fibrosis and Creeping Fat in Crohn's Disease
Intestinal stricture remains one of the most challenging complications in Crohn's disease, and its underlying mechanisms are poorly understood. Accumulating evidence suggests that gut microbiota is significantly altered in stenotic intestines and may play a key role in the development of fibrogenesis in Crohn's disease. Additionally, the presence of hypertrophic mesenteric adipose tissue, also known as creeping fat, is closely correlated with intestinal stricture and fibrosis. Recent findings have revealed that bacterial translocation to creeping fat might exacerbate colitis and promote intestinal fibrosis. However, there is still a gap in determining whether gut microbiota links the formation of creeping fat to intestinal fibrosis. Hence, this review aims to summarize the known microbial influences on intestinal fibrosis, describes the microbial characteristics of creeping fat in Crohn's disease, and discusses the crosstalk between creeping fat‐associated dysbiosis and the development of intestinal fibrosis.